Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,121.56
(
0.81%
)
US TECH 100
26,137.60
(
1.41%
)
Dow Jones
49,433.24
(
-0.03%
)
Brent Oil
97.23
(
2.34%
)
Bitcoin
78,829.45
(
3.28%
)
News Focus
News Focus
Post# of 517484
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

WilliamMunny

Send PM Follow Ignore
Followers 8
Posts 494
Boards Moderated 0
Alias Born 03/06/2022

WilliamMunny

Re: Jimbo50 post# 504660

Monday, 10/27/2025 1:01:25 PM

Monday, October 27, 2025 1:01:25 PM

Post# of 517484
Good catch, Jimbo. This quote on the PR from Biogen regarding the conditional nature of the approval in Canada: "LEQEMBI has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit. Eisai plans to submit clinical assessment data captured from participants in real-world clinical practice."
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News